A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors

PURPOSE: We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs. MATERIALS AND METHODS: This single-ar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res Treat
Principais autores: Han, Ji-Youn, Lee, Ki Hyeong, Kim, Sang-We, Min, Young Joo, Cho, Eunkyung, Lee, Youngjoo, Lee, Soo-Hyun, Kim, Hyae Young, Lee, Geon Kook, Nam, Byung Ho, Han, Hyesun, Jung, Jina, Lee, Jin Soo
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Cancer Association 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5266390/
https://ncbi.nlm.nih.gov/pubmed/27188206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2016.058
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados